Radiopharmaceuticals in the spotlight (part II)

Scientific & market coverage of $PNT, $LNTH, $RYZB, $FUSN, $ATNM, $CLRB, and a few big pharmas ($LLY, $NVS, $JNJ)

This morning, Eli Lilly (LLY) acquired Point Bio (PNT) for $12.50/share, an 87% premium. The $1.4B price tag gives Lilly a strong presence in radiopharmaceuticals for solid tumor cancers. We wrote about the radiopharmaceutical space here, and are now starting to see some of the catalysts play out.
 
A Low-Risk Acquisition for Lilly
Point had $400M in cash …